drugset / Trial / NCT04385186

Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19

NCT04385186 ↗

Phase 2 Unknown 60 enrolled National Blood Center Foundation, Hemolife
RandomizedParallel-groupSingle-blindTreatment

Summary

Convalescent plasma is a way to provide passive immunity to a person exposed to an infectious agent. It has been used as a therapeutic tool for emerging viral infections without specific treatment and with high morbidity and mortality, such as Influenza H1N1, H5N1, H7N9, Ebola, MERS, SARS-CoV1, and even SARS-Cov2, with satisfactory results regarding evolution clinic of patients treated and without significant adverse events reported. One of its main advantages of convalescent plasma is to generate a rapid immune response (even faster than a vaccine), against a pathogen that circulates in a specific geographic area, probably common for both donor and recipient.

Timeline

Start
2020-06-20
Primary completion
2020-11-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated convalescent plasma Unknown 200 ml Other

Indications